Perspective Therapeutics, Inc. (CATX)

9,97 +0,10 (+1,01 %) À la clôture : 04:00PM EDT

Perspective Therapeutics, Inc.

2401 Elliott Avenue
Suite 320
Seattle, WA 98121
United States
206-676-0900
https://www.perspectivetherapeutics.com

Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 116

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Johan M. Spoor	CEO & Director	855,78k	S.O.	1972
Mr. Jonathan R. Hunt	CFO & Co-Principal Financial Officer	944,35k	S.O.	1967
Dr. Markus Puhlmann M.B.A., M.D.	Chief Medical Officer	633,14k	S.O.	1966
Mr. Shane Cobb	Executive Vice President of Operations	S.O.	S.O.	S.O.
Mr. Mark J. Austin CPA	VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary	S.O.	S.O.	1987
Dr. Michael K. Schultz Ph.D.	Chief Science Officer	S.O.	S.O.	S.O.
Mr. Andrew Bright	Executive Vice President of Brachytherapy	S.O.	S.O.	S.O.
Mr. Amos Hedt BA, PGradDip	Chief Business Strategy Officer	S.O.	S.O.	S.O.
Dr. Frances L. Johnson M.D.	Chief Innovation Officer	S.O.	S.O.	S.O.
Mr. David Hauser Ph.D.	Senior Vice President of Clinical Operations	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Perspective Therapeutics, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.